AIVIS Inc. (CEO Daehong Lee), a company specializing in AI-based pathology analysis solutions, announced that its AI research team — Geonwoo Noh, Kyungtae Min, and Changhyun Song — won second place in the UNICORN Challenge at MICCAI 2025, one of the world’s leading medical AI conference. MICCAI (Medical Image Computing and Computer-Assisted Intervention) is the most prestigious international academic conference in the field of medical artificial intelligence, where experts and scholars from around the world gather annually to exchange the latest research and technological advances. AIVIS’s latest achievement is particularly meaningful, as it officially demonstrates on a global stage the excellence and versatility of the company’s proprietary foundation model technology, developed specifically for pathology image analysis through in-house research and development. Validating the Power of Foundation Models in AI-Driven Pathology The UNICORN Challenge hosted by MICCAI 2025 focused on evaluating the generalizability and versatility of AI models from companies and research institutions worldwide. AIVIS won second place in the Pathology Vision Track, one of the competition’s core categories that tests the performance of foundation models in pathology image analysis. In this challenge, participants were evaluated on how well a single, general-purpose AI model could accurately analyze large-scale pathology images from previously unseen organs, stains, and disease types — and how effectively it could adapt to different tasks without prior training. Unlike traditional narrow AI, which is optimized for specific datasets or diseases, this challenge required models to prove their capability to perform consistently across a wide range of pathology data — a true test of foundation model technology. Global Recognition for AIVIS’s Technological Excellence AIVIS participated in the challenge leveraging years of accumulated expertise in pathology AI image analysis. By combining its proprietary pathology analysis technology with its foundation model, AIVIS achieved exceptionally high accuracy and stable performance on the diverse, unseen test datasets provided by the organizers. The company’s model outperformed numerous global corporations and university research teams, ultimately earning the runner-up award. This accomplishment once again confirms that AIVIS possesses not only competitive AI solutions but also world-class core foundation model technology. Strong foundation model capabilities serve as a key competitive advantage for future AI solution development — enabling fast, efficient creation of specialized models for cancer diagnosis, prognosis prediction, and biomarker discovery with minimal additional training. AIVIS to Accelerate AI Commercialization in Precision Medicine “We are pleased that our AI research team’s proprietary foundation model technology has been officially recognized at MICCAI 2025, where the world’s top AI experts convene,” said Daehong Lee, CEO of AIVIS. “Building on this success, we will continue to enhance the accuracy and efficiency of pathology diagnostics and accelerate the commercialization of innovative AI solutions that can help reshape the paradigm of precision medicine.”